SKI II
|
|
|
- CAS-Nr.
- 312636-16-1
- Englisch Name:
- SKI II
- Synonyma:
- SphK-I2;CS-1145;SKI II;SKI-II;SKI II - SKI 2;SKI II (SphK-I2);SKI II USP/EP/BP;SKIII(SphK-I2), >98%;Sphingosine Kinase Inhibitor;Sphingosine Kinase Inhibitor 2;SKI II (Sphingosine Kinase Inhibitor)
- CBNumber:
- CB1498400
- Summenformel:
- C15H11ClN2OS
- Molgewicht:
- 302.78
- MOL-Datei:
- 312636-16-1.mol
|
SKI II Eigenschaften
- Siedepunkt:
- 507.1±60.0 °C(Predicted)
- Dichte
- 1.415±0.06 g/cm3(Predicted)
- RTECS-Nr.
- SK5900000
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO: ≥20 mg/mL
- Aggregatzustand
- solid
- pka
- 10.17±0.26(Predicted)
- Farbe
- off-white
- Sensitive
- Air & Light Sensitive
- CAS Datenbank
- 312636-16-1
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
SKI II Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
SKI II is a nonlipid inhibitor of sphingosine kinase. SKI II s orally bioavailable and has shown significant inhibition of tumor growth in mice.
Biologische Aktivität
Selective non-lipid inhibitor of sphingosine kinase (IC 50 = 0.5 μ M); does not act at ATP-binding site. Displays no inhibition of ERK2, PI 3-kinase, or PKC α at concentrations up to 60 μ M. Reduces levels of sphingosine-1-phosphate in MDA-MB-231 breast cancer cells. Induces apoptosis and inhibits proliferation in several other tumor cell lines in vitro (IC 50 = 0.9-4.6 μ M).
Biochem/physiol Actions
Sphingosine kinase (SK) plays a pivotal role in regulating tumor growth and SK can act as an oncogene. Expression of SK RNA is significantly elevated in a variety of solid tumors, compared with normal tissue from the same patient. A number of novel inhibitors of human SK were identified, and several representative compounds were characterized in detail. These compounds demonstrated activity at sub- to micromolar concentrations, making them more potent than any other reported SK inhibitor, and were selective toward SK compared with a panel of human lipid and protein kinases. Kinetic studies revealed that the compounds were not competitive inhibitors of the ATP-binding site of SK. 4-[4-(4-chloro-phenyl)-thiazol-2-ylamino]-phenol (SKI-II) inhibitor is orally bioavailable, detected in the blood for at least 8 h, and showed a significant inhibition of tumor growth in mice with IC50 = 0.5 μM; SKI II does not act at ATP-binding site. Displays no inhibition of ERK2, PI 3-kinase, or PKCa at concentrations up to 60 μM.SKI II induces apoptosis and inhibits proliferation in several other tumor cell lines in vitro (IC50 = 0.9-4.6 μM).
SKI II Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
SKI II Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 113)Lieferanten
- Sphingosine Kinase Inhibitor
- Sphingosine Kinase Inhibitor 2
- SKI II (SphK-I2)
- SphK-I2
- SKI II (Sphingosine Kinase Inhibitor)
- Phenol, 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]-
- 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol
SKI II
- 4-(4-(4-chlorophenyl)thiazol-2-ylamino)phenol
- SKI II;SKI-II
- SKIII(SphK-I2), >98%
- SKI II - SKI 2
- SPHINGOSINE KINASE INHIBITOR;SPHINGOSINE KINASE INHIBITOR 2;SKI II (SPHK-I2);SPHK-I2;SKI II (SPHINGOSINE KINASE INHIBITOR)
- CS-1145
- 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
- SKI II USP/EP/BP
- SKI II,Sphingosine kinase,Apoptosis,SphK,Wnt,Inhibitor,inhibit
- 4-(4-chlorophenyl)-N-(p-tolyl)thiazol-2-amine
- 312636-16-1
- Inhibitors
- Lysophospholipid receptor and related
